Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
Greta Bagnolini, Domenico Milano, Marcella Manerba, Fabrizio Schipani, Jose Antonio Ortega, Dario Gioia, Federico Falchi, Andrea Balboni, Fulvia Farabegoli, Francesca Franco, Janet Robertson, Roberto Pellicciari, Isabella Pallavicini, Sebastiano Peri, Saverio Minucci, Stefania Girotto, Giuseppina Di Stefano, Marinella Roberti, Andrea Cavalli
Abstract
-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.
Topics & Concepts
OlaparibSynthetic lethalityHomologous recombinationRAD51LethalityCancer researchSmall moleculePancreatic cancerChemistryPARP inhibitorBRCA2 ProteinMutationCancerPoly ADP ribose polymeraseDNA repairBiologyGeneticsGermline mutationPolymeraseDNABiochemistryGenePARP inhibition in cancer therapyDNA Repair MechanismsCRISPR and Genetic Engineering